AINOS INC
AIMDNASDAQTrading Snapshot
- Day Range
- $1.22 – $1.25
- 52-Week Range
- $1.25 – $4.44
- Volume
- $2.52B
- Avg Volume
- $2.74B
- Shares Outstanding
- 7.4M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $124,157
- Last Q Revenue
- $152
- P/E Ratio
- -0.5
- P/S Ratio
- 720.2x
- EPS (TTM)
- $-1.96
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −36.5%
Why Investors Own AIMD
- ✓High-growth profile — revenue up +43.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
AINOS INC
AIMD
StockOtter · stockotter.spaceAbout AINOS INC
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Ainos Completes Delivery of 1,400 AI Nose Systems to ASE Under $2.1 Million, Three-Year Contract
Preparations underway for a larger-scale second-phase deployment specified in the existing MOU, building on first-phase deployment experience Advanced packaging deployment marks a major step for Ainos' Chemical Intellige
Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical Intelligence
Initial license payment tied to near-term contractual delivery; additional payment opportunities may arise during development, before drug approval Partner assumes assigned clinical and regulatory funding and execution,
Ainos, Inc. (NASDAQ:AIMD) Shares Shorted: Short Interest Up 172.6% in September
Ainos, Inc. (NASDAQ: AIMD - Get Free Report) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totaling 55,787 shares, a growth of 172.6% from the August 3
Ainos and BioPhoenix Sign VELDONA License Agreement, Establishing a Potential $10 Million Collaboration Framework
Partner-funded development marks an important milestone for VELDONA, with BioPhoenix funding and advancing clinical and regulatory development for two initial indications Development funding is additional to the framewor
VASRO Research Highlights Ainos' New Order, Semiconductor Commercial Momentum and 1 Billion+ Chemical Dataset
Report points to front-end semiconductor orders, a $2.1 million back-end program and continued dataset expansion as key indicators of Ainos' growing commercial scale HOUSTON, TX / ACCESS Newswire / September 16, 2026 / A
Ainos Advances AI Nose into Commercial Deployment in Front-End Semiconductor Manufacturing
Initial commercial orders mark progress toward broader commercial adoption and support revenue-generation opportunities beginning in 2H 2026 Proprietary real-world chemical dataset surpasses 1 billion records, strengthen